NRx Pharmaceuticals (NRXP) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Document Information [Line Items]
Entity Central Index Key	0001719406
Entity Registrant Name	NRX Pharmaceuticals, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-38302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2844431
Entity Address, Address Line One	1201 Orange Street, Suite 600
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	484
Local Phone Number	254-6134
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,894,693
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	NRXPW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	NRXP
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 1,898	$ 4,595
Prepaid expense and other current assets	2,982	2,289
Total current assets	4,880	6,884
Other assets	384	431
Total assets	5,264	7,315
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	5,015	4,632
Accrued and other current liabilities	9,594	4,714
Accrued clinical site costs	444	524
Convertible note payable and accrued interest	7,651	9,161
Insurance loan payable	943	0
Warrant liabilities (Note 9)	8	17
Total liabilities	23,655	19,048
Commitments and Contingencies (Note 8)
Common stock, $0.001 par value, 500,000,000 shares authorized; 10,791,630 and 8,391,940 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	11	8
Additional paid-in capital	249,173	241,406
Accumulated other comprehensive loss	(3)	(3)
Accumulated deficit	(267,572)	(253,147)
Total stockholders’ deficit	(18,391)	(11,733)
Total liabilities and stockholders' deficit	5,264	7,315
Nondesignated Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 50,000,000 shares authorized.	0	0
Series A Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 50,000,000 shares authorized.	$ 0	$ 3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, authorized (in shares)	50,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	10,791,630	8,391,940
Common stock, outstanding (in shares)	10,791,630	8,391,940
Nondesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	50,000,000	50,000,000
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	12,000,000	12,000,000
Preferred stock, issued (in shares)	0	3,000,000
Preferred stock, outstanding (in shares)	0	3,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expense:
Research and development	$ 2,804	$ 3,873	$ 4,552	$ 7,523
General and administrative	4,246	4,065	8,496	9,850
Settlement expense	0	250	0	250
Total operating expenses	7,050	8,188	13,048	17,623
Loss from operations	(7,050)	(8,188)	(13,048)	(17,623)
Other (income) expense:
Interest income	(7)	(145)	(34)	(301)
Interest expense	0	0	230	0
Convertible note default penalty	849	0	849	0
Change in fair value of convertible note payable	23	663	341	2,435
Change in fair value of warrant liabilities	(18)	11	(9)	(1)
Total other expense	847	529	1,377	2,133
Net loss	(7,897)	(8,717)	(14,425)	(19,756)
Comprehensive loss:
Change in fair value of convertible note attributed to credit risk	0	128	0	22
Other comprehensive loss	0	128	0	22
Comprehensive loss	$ (7,897)	$ (8,845)	$ (14,425)	$ (19,778)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.75)	$ (1.21)	$ (1.49)	$ (2.81)
Weighted average common shares outstanding:
Basic and diluted (in shares)	10,517,460	7,322,156	9,684,873	7,026,062

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock and Warrant Issuance [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Common Stock [Member]	Common Stock and Warrant Issuance [Member] Additional Paid-in Capital [Member]	Common Stock and Warrant Issuance [Member] Retained Earnings [Member]	Common Stock and Warrant Issuance [Member] AOCI Attributable to Parent [Member]	Common Stock and Warrant Issuance [Member]	ATM Offering [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	ATM Offering [Member] Preferred Stock [Member]	ATM Offering [Member] Common Stock [Member]	ATM Offering [Member] Additional Paid-in Capital [Member]	ATM Offering [Member] Retained Earnings [Member]	ATM Offering [Member] AOCI Attributable to Parent [Member]	ATM Offering [Member]	Private Placement [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022																						0	0	6,644,299
Balance at Dec. 31, 2022																						$ 0	$ 0	$ 7	$ 230,399	$ (222,997)	$ 0	$ 7,409
Stock-based compensation																						0	0	0	695	0	0	695
Stock issuances, net (in shares)	0	0	386,667
Stock issuances, net	$ 0	$ 0	$ 0	$ 2,545	$ 0	$ 0	$ 2,545
Net loss																						$ 0	$ 0	$ 0	0	(11,039)	0	(11,039)
Balance (in shares) at Mar. 31, 2023																						0	0	7,030,966
Balance at Mar. 31, 2023																						$ 0	$ 0	$ 7	233,639	(234,036)	106	(284)
Change in fair value of convertible note attributed to credit risk																						$ 0	$ 0	$ 0	0	0	106	106
Balance (in shares) at Dec. 31, 2022																						0	0	6,644,299
Balance at Dec. 31, 2022																						$ 0	$ 0	$ 7	230,399	(222,997)	0	7,409
Net loss																												(19,756)
Balance (in shares) at Jun. 30, 2023																						0	0	8,038,833
Balance at Jun. 30, 2023																						$ 0	$ 0	$ 8	239,959	(242,753)	(22)	(2,808)
Change in fair value of convertible note attributed to credit risk																												(22)
Balance (in shares) at Mar. 31, 2023																						0	0	7,030,966
Balance at Mar. 31, 2023																						$ 0	$ 0	$ 7	233,639	(234,036)	106	(284)
Stock-based compensation																						$ 0	$ 0	$ 0	544	0	0	544
Stock issuances, net (in shares)	0	0	967,000
Stock issuances, net	$ 0	$ 0	$ 1	5,576	0	0	5,577
Shares issued as repayment of principal and interest for convertible note (in shares)																						0	0	40,867
Shares issued as repayment of principal and interest for convertible note																						$ 0	$ 0	$ 0	200	0	0	200
Net loss																						$ 0	$ 0	$ 0	0	(8,717)	0	(8,717)
Balance (in shares) at Jun. 30, 2023																						0	0	8,038,833
Balance at Jun. 30, 2023																						$ 0	$ 0	$ 8	239,959	(242,753)	(22)	(2,808)
Change in fair value of convertible note attributed to credit risk																						$ 0	$ 0	$ 0	0	0	(128)	(128)
Balance (in shares) at Dec. 31, 2023																						3,000,000	0	8,391,940
Balance at Dec. 31, 2023																						$ 3	$ 0	$ 8	241,406	(253,147)	(3)	(11,733)
Stock-based compensation																						$ 0	$ 0	$ 0	242	0	0	242
Conversion of Series A preferred stock into common stock (in shares)																							0	300,000
Conversion of Series A preferred stock into common stock																							$ 0	$ 0	3	0	0	0
Conversion of Series A preferred stock into common stock (in shares)																						(3,000,000)
Conversion of Series A preferred stock into common stock																						$ (3)
Stock issuances, net (in shares)	0	0	575,000					0	0	34,584					0	0	270,000
Stock issuances, net	$ 0	$ 0	$ 1	1,343	0		1,344	$ 0	$ 0	$ 0	$ 179	$ 0	$ 0	$ 179	$ 0	$ 0	$ 0	$ 1,027	$ 0	$ 0	$ 1,027
Warrants issued pursuant to the Alvogen Agreement amendment (see Note 6)																						$ 0	$ 0	$ 0	0	0	0	0
Vesting of restricted stock awards (in shares)																						0	0	57,500
Vesting of restricted stock awards																						$ 0	$ 0	$ 0	0	0	0	0
Shares issued as repayment of principal and interest for convertible note (in shares)																						0	0	143,648
Shares issued as repayment of principal and interest for convertible note																						$ 0	$ 0	$ 1	399	0	0	400
Net loss																						$ 0	$ 0	$ 0	0	(6,528)	0	(6,528)
Balance (in shares) at Mar. 31, 2024																						0	0	9,772,672
Balance at Mar. 31, 2024																						$ 0	$ 0	$ 10	244,599	(259,675)	(3)	(15,069)
Balance (in shares) at Dec. 31, 2023																						3,000,000	0	8,391,940
Balance at Dec. 31, 2023																						$ 3	$ 0	$ 8	241,406	(253,147)	(3)	(11,733)
Net loss																												(14,425)
Balance (in shares) at Jun. 30, 2024																						0	0	10,791,630
Balance at Jun. 30, 2024																						$ 0	$ 0	$ 11	249,173	(267,572)	(3)	(18,391)
Change in fair value of convertible note attributed to credit risk																												0
Balance (in shares) at Mar. 31, 2024																						0	0	9,772,672
Balance at Mar. 31, 2024																						$ 0	$ 0	$ 10	244,599	(259,675)	(3)	(15,069)
Stock-based compensation																						0	0	0	97	0	0	97
Stock issuances, net (in shares)	0	0	698,050					0	0	247,868
Stock issuances, net	$ 0	$ 0	$ 1	$ 1,913	$ 0	$ 0	$ 1,914	$ 0	$ 0	$ 0	$ 1,228	$ 0	$ 0	$ 1,228
Net loss																						$ 0	$ 0	$ 0	0	(7,897)	0	(7,897)
Issuance of shares related to reverse stock split (in shares)																						0	0	73,040
Contract cost related to Alvogen termination (see Note 6)																						$ 0	$ 0	$ 0	1,336	0	0	1,336
Balance (in shares) at Jun. 30, 2024																						0	0	10,791,630
Balance at Jun. 30, 2024																						$ 0	$ 0	$ 11	$ 249,173	$ (267,572)	$ (3)	(18,391)
Change in fair value of convertible note attributed to credit risk																												$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Common Stock and Warrant Issuance [Member]
Offering costs	$ 494	$ 481	$ 2,168	$ 351
ATM Offering [Member]
Offering costs	$ 118	$ 48

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,425)	$ (19,756)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2	2
Stock-based compensation	339	1,239
Change in fair value of warrant liabilities	(9)	(1)
Change in fair value of convertible note payable	341	2,435
Warrant issuance costs related to Alvogen termination	1,336	0
Convertible note default penalty	849	0
Non-cash settlement expense	0	250
Changes in operating assets and liabilities:
Prepaid expense and other assets	(648)	922
Accounts payable	4,209	129
Insurance loan payable	943	0
Accrued expense and other liabilities	830	879
Net cash used in operating activities	(6,233)	(13,901)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment	0	(2)
Net cash used in investing activities	0	(2)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of convertible note	(2,156)	(90)
Proceeds from issuance of insurance loan	0	786
Proceeds from issuance of common stock and warrants, net of issuance costs	4,665	0
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs	1,027	8,122
Net cash provided by financing activities	3,536	8,818
Net decrease in cash and cash equivalents	(2,697)	(5,085)
Cash and cash equivalents at beginning of period	4,595	20,054
Cash and cash equivalents at end of period	1,898	14,969
Supplemental disclosure of cash flow information:
Cash paid for interest	374	205
Cash paid for taxes	0	0
Non-cash investing and financing activities
Issuance of common stock warrants as offering costs	188	75
Conversion of Series A Preferred Stock to Common stock [Member]
Non-cash investing and financing activities
Conversion of Series A preferred stock into common stock	3	0
Conversion of Principal and Interest Into Common Stock [Member]
Non-cash investing and financing activities
Issuance of common stock as principal and interest repayment for convertible notes	$ 400	$ 200

Note 1 - Organization

Note 1 - Organization	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Business NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“ NRX Company NeuroRx HOPE Company we us our PTSD NMDA R&D two FDA PDUFA June 2025: 101, 100, February 2024, August 2024 7 Operations The Company’s drug development activities have expanded from its original focus on development of NRX- 101, 101 100/HTX 100

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal year and has a working capital deficit at June 30, 2024 2024. 2025, first may not As of June 30, 2024 August 12, 2024, $16.3 The Company has now secured operating capital that it anticipates as sufficient to fund its drug development operations through year end and to finance submission of FDA New Drug Applications for NRX- 100 101 2024. may 2024 may twelve The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. On April 1, 2024, Reverse Stock Split Common Stock 1 10 9. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP FASB ASC SEC not not may Use of Estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible note payable, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not third Fair Value of Financial Instruments FASB ASC Topic 820, Fair Value Measurements ASC 820 The accounting guidance classifies fair value measurements in one three Level 1: Level 2: 1 Level 3: no 11 Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not may, June 30, 2024 not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three may Revenue Recognition The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers ASC 606 not may may The Company enters into contractual arrangements that may 606, may The License Agreement (the “ License Agreement Alvogen 6 606. 606, 606, five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five At contract inception, once the contract is determined to be within the scope of ASC 606, may not The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may not The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. The Company’s revenue arrangements may Milestone Payments: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first not Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Research Services: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note 6 Research and Development Costs Research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Non-cancellable Contracts The Company may may Convertible Note Payable and Fair Value Election As permitted under FASB ASC Topic 825, ASC 825 The Company estimates the fair value of the note payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility and volume volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimate its expected future equity and volume volatility based on the historical volatility of both its Common Stock price and Common Stock trading volume utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six December 31, 2023, June 30, 2024, Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations and comprehensive loss based upon the underlying individual’s role at the Company. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ASC 480 815, Derivatives and Hedging ASC 815 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not 9 11 Modification of Warrants A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may Preferred Stock In accordance with ASC 480, not 815 40, Derivatives and Hedging Contracts in an Entity s Own Equity not not 815. Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ASC 740 not not 740. not not Loss Per Share The Company applies the two two no two not Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. Six months ended June 30, 2024 2023 Stock options 161,437 254,885 Restricted stock awards 66,666 100,000 Common stock warrants 4,069,240 3,002,159 Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. For the six June 30, 2024 no

Note 4 - Prepaid Expense and Ot

Note 4 - Prepaid Expense and Other Current Assets	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	4. Prepaid Expense and Other Current Assets Prepaid expense and other current assets consisted of the following at the dates indicated (in thousands): June 30, 2024 December 31, 2023 (Unaudited) Prepaid expense and other current assets: Prepaid insurance $ 1,500 $ 1,078 Prepaid clinical development costs 830 871 Other prepaid expense 646 334 Other current receivables 6 6 Total prepaid expense and other current assets $ 2,982 $ 2,289

Note 5 - Accrued and Other Curr

Note 5 - Accrued and Other Current Liabilities	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. Accrued and other current liabilities consisted of the following at the dates indicated (in thousands): June 30, 2024 December 31, 2023 (Unaudited) Accrued and other current liabilities: Refund liability (see Note 6) $ 3,826 $ — Professional services 3,593 2,686 Accrued employee costs 1,062 835 Accrued research and development expense 900 1,112 Other accrued expense 213 81 Total accrued and other current liabilities $ 9,594 $ 4,714

Note 6 - Alvogen Licensing Agre

Note 6 - Alvogen Licensing Agreement	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	6. In June 2023, 101, first 2b/3 First Milestone Payment February 2024, June 30, 2024). three 9 second first 2 first not September 3, 2024, not not Termination Under the License Agreement, as amended, Alvogen was granted early termination rights. On June 21, 2024, not June 30, 2024. Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination. As of June 30, 2024, June 30, 2024, not

Note 7 - Debt

Note 7 - Debt	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Convertible Note On November 4, 2022, Note Streeterville The initial terms of the Note included the following provisions, certain of which have subsequently been modified as described below. The Company has the option to prepay the Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. The noteholder has the right to redeem up to $1.0 million of the outstanding balance of the Note per month starting six Maximum Monthly Redemption Amount may Redemption Premium Redemption Conversion Price two ten May 1, 2023, fifty 50% ten 10 thirty 30% ten 10 The Note contains certain Trigger Events (as defined in the Note) that generally, if uncured within five may Event of Default may may Due to these embedded features within the Note, the Company elected to account for the Note at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the consolidated statements of operations. Convertible Note Amendments On March 30, 2023, First Amendment On July 7, 2023, #2 Second Amendment July 10, 2023, July 10, 2023. July 31, 2023, December 31, 2023 ( may not July 31, 2023 December 31, 2023. may On February 9, 2024, #3 Third Amendment February 12, 2024, February 12, 2024. February 29, 2024, July 31, 2024, first three may not After April 30, 2024, July 31, 2024, may July 31, 2024, July 31, 2024, August 31, 2024. not three June 30, 2024. During the Minimum Payment Period (defined in the Note, as amended), the Company is permitted to pay the Redemption Amounts in the form of shares of Common Stock of the Company (the “ Redemption Conversion Shares Both the Second Amendment and the Third Amendment (considered cumulatively with the Second Amendment) were deemed to be debt modifications in accordance with FASB ASC Topic 470, Debt not Convertible Note Fair Value Measurements The Company estimates the fair value of the Note using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility and volume volatility of its Common Stock, the time to expiration of the Note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future volatility based on the actual volatility of its Common Stock and historical volatility of its Common Stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six The discount to the principal amount is included in the carrying value of the Note. During 2022, three six June 30, 2024, three six June 30, 2023, During the three six June 30, 2024 three six June 30, 2023 As of June 30, 2024 December 31, 2023 11 Alleged Default On April 24, 2024, Notice Spin-Off April 8, 2024, April 3, 2024 Streeterville also filed a complaint (the “ Complaint no On July 29, 2024, 14

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Sarah Herzog Memorial Hospital License Agreement The Company is required to make certain payments related to the development of NRX- 101 Licensed Product SHMH SHMH License Agreement Milestone Payments End of Phase I Clinical Trials of Licensed Product (completed) $ 100,000 End of Phase II Clinical Trials of Licensed Product (completed) $ 250,000 End of Phase III Clinical Trials of Licensed Product $ 250,000 First Commercial Sale of Licensed Product in U.S. $ 500,000 First Commercial Sale of Licensed Product in Europe $ 500,000 Annual Revenues Reach $100,000,000 $ 750,000 The milestone payments due above may three six June 30, 2024 2023 Royalties A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least one not one not may not Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the three six June 30, 2023 Annual Maintenance Fee A fixed amount of $100,000 was paid on April 16, 2021 Exclusive License Agreement The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent 8,653,120 101 three six June 30, 2024 2023 no Legal Proceedings The Company is a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. See Note 7, no On July 29, 2024, June 30, 2024. On August 12, 2024, 14 The Company is currently involved in and may not

Note 9 - Equity

Note 9 - Equity	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	9. Common Stock Reverse Stock Split On March 21, 2024, 1 March 28, 2024, Amendment 4:30 April 1, 2024 ( Effective Time ten one At the Effective Time of April 1, 2024, one No one Preferred Stock Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has 50,000,000 shares of preferred stock with a par value of $0.001, of which 12,000,000 were designated Series A Convertible Preferred Stock ( "Series A Preferred" August 2023, March 2024 June 30, 2024 Common Stock Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized 500,000,000 shares of Common Stock with a par value of $0.001. On January 2, 2024, From February 20, 2024 April 15, 2024, ATM Purchase Agreements April 15, 2024, August 14, 2023 ( Offering Agreemen Current Prospectus Supplement June 30, 2024, On February 29, 2024, February February 2024 February February 2024 4 2 1933, Securities Act February 2024 June 30, 2024 not On February 27, 2024, February Representative February February 2024 February February February February 45 February February February 2024 February February 28, 2024, February 2024 February February 2024 March 5, 2024, February February February 27, 2024, February February March 6, 2024. February On April 18, 2024, April April April 2024 A pril Shares April 45 April April April 2024 April April 19, 2024, April April 2024 May 23, 2024, April April April 18, 2024, April April May 23, 2024. April Common Stock Warrants Substitute Warrants In connection with the Merger in 2021, "BRPA" Substitute Warrants 815, 820, The Company recognized a loss on the change in fair value of the Substitute Warrants for the three June 30, 2024 2023 six June 30, 2024 2023 11 Assumed Public Warrants Prior to the Merger, the Company had 3,450,000 warrants outstanding (the “ Public Warrants one tenth five During the three six June 30, 2024 2023 no June 30, 2024 December 31, 2023 Assumed Private Placement Warrants Prior to the Merger, the Company had outstanding 136,250 Private Placement Warrants (the “ Private Placement Warrants not 815 40 15 not June 30, 2024 December 31, 2023 The Company recognized a loss on the change in fair value of the Private Placement Warrants for the three June 30, 2024 2023 six June 30, 2024 2023 11 Investor Warrants As discussed above, on February 28, 2024, February February six five February On February 28, 2024, February six five On March 5, 2024 February On April 19, 2024, April April April six five April On May 23, 2024 April Alvogen Warrants In conjunction with the amended Alvogen licensing agreement discussed in Note 6, February 7, 2024 three may no may not 61 March 31, 2024. June 21, 2024, Weighted Average Weighted Aggregate Total Remaining Average Intrinsic Value Warrant Shares Term Exercise Price (in thousands) Outstanding as of December 31, 2023 3,321,499 3.91 $ 23.01 $ 180 Issued 718,348 Expired (5,510 ) Outstanding as of March 31, 2024 4,034,337 3.68 19.61 807 Issued 34,903 Outstanding as of June 30, 2024 4,069,240 3.44 $ 19.47 $ —

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	10. 20 16 Prior to the Merger, NRx maintained its 2016 2016 2016 In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of 0.316:1 Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate 289,542 shares of the Company’s Common Stock at an average exercise price of $51.00 per share. 2021 As of June 30, 2024 2021 2021 January 1, 2024 2021 January 1, 2022 January 1, 2031, December 28, 2023 first 2021 may 100% June 30, 2024 2021 2021 Option Awards The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not NRX‑101, The Company issued no stock options during the three six June 30, 2024 The following table summarizes the Company’s employee and non-employee stock option activity under the 2021 Number of shares Weighted average exercise price Weighted average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2023 264,983 $ 18.30 7.7 $ 75 Expired/Forfeited (89,546 ) Outstanding as of March 31, 2024 175,437 $ 18.60 8.4 $ 40 Expired/Forfeited (14,000 ) Outstanding as of June 30, 2024 161,437 $ 21.18 7.5 $ — Options vested and exercisable as of June 30, 2024 126,882 $ 25.18 7.0 $ — Stock-based compensation expense related to stock options was $0.1 million and $0.3 million for the three six June 30, 2024 At June 30, 2024 Restricted Stock Awards The following table presents the Company’s Restricted Stock Activity: Awards Weighted Average Grant Date Fair Value Balance as of December 31, 2023 (unvested) 124,166 $ 5.20 Vested (57,500 ) 4.64 Balance as of March 31, 2024 (unvested) 66,666 5.66 Vested — — Balance as of June 30, 2024 (unvested) 66,666 $ 5.66 On July 12, 2022, RSAs three On December 28, 2023, six September 4, 2023, Stock-based compensation expense related to RSAs was less than $0.1 million for the three six June 30, 2024 As of June 30, 2024 The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands): Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 (Unaudited) Stock-based compensation expense General and administrative $ 72 $ 443 $ 283 $ 1,034 Research and development 25 101 56 205 Total stock-based compensation expense $ 97 $ 544 $ 339 $ 1,239

Note 11 - Fair Value Measuremen

Note 11 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three six June 30, 2024 2023 Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 1 3 June 30, 2024 December 31, 2023 Description Level June 30, 2024 December 31, 2023 Assets: (Unaudited) Money Market Account 1 $ 475 $ 3,874 Liabilities: Warrant liabilities (Note 9) 3 $ 8 $ 17 Convertible note payable (Note 7) 3 $ 7,651 $ 9,161 Convertible Note Payable The significant inputs used in the Monte Carlo simulation to measure the convertible note liability that is categorized within Level 3 June 30, 2024 2023 Stock price on valuation date $ 2.44 $ 4.84 Time to expiration 0.17 0.84 Note market interest rate 20.6 % 8.9 % Equity volatility 145.0 % 100.0 % Volume volatility 560.0 % 455.0 % Risk-free rate 5.48 % 5.42 % Probability of default 50.0 % 6.5 % The following table sets forth a summary of the changes in the fair value of the Note categorized within Level 3 Fair value of the Note as of December 31, 2023 $ 9,161 Conversions and repayments of principal and interest (shares and cash) (2,700 ) Fair value adjustment through earnings 318 Fair value adjustment through accumulated other comprehensive loss — Fair value of the Note as of March 31, 2024 6,779 Conversions and repayments of principal and interest (shares and cash) — Fair value adjustment through earnings 23 Default penalty 849 Fair value adjustment through accumulated other comprehensive loss — Fair value of the Note as of June 30, 2024 $ 7,651 Convertible note payable - current portion $ 7,651 Convertible note payable, net of current portion $ — Fair value of the Note as of December 31, 2022 $ 10,525 Conversions and repayments of principal and interest (shares and cash) — Fair value adjustment through earnings 1,770 Fair value adjustment through accumulated other comprehensive loss (106 ) Fair value of the Note as of March 31, 2023 12,189 Conversions and repayments of principal and interest (shares and cash) (288 ) Fair value adjustment through earnings 665 Fair value adjustment through accumulated other comprehensive loss 128 Fair value of the Note as of June 30, 2023 $ 12,694 Convertible note payable - current portion $ 12,694 Convertible note payable, net of current portion $ — Warrant Liabilities The Company utilizes a Black-Scholes model approach to value the Private Placement Warrants and Substitute Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liabilities is determined using Level 3 no zero The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 June 30, 2024 2023 Stock price on valuation date $ 2.44 $ 6.60 Exercise price per share $ 115.00 $ 115.00 Expected life 1.90 3.15 Volatility 176.9 % 175.1 % Risk-free rate 4.8 % 5.3 % Dividend yield 0.0 % 0.0 % Fair value of warrants $ 0.60 $ 7.93 A reconciliation of warrant liabilities is included below (in thousands): Balance as of December 31, 2023 $ 17 Loss upon re-measurement 9 Balance as of March 31, 2024 26 Gain upon re-measurement (18 ) Balance as of June 30, 2024 $ 8 Balance as of December 31, 2022 $ 37 Gain upon re-measurement (12 ) Balance as of March 31, 2023 25 Loss upon re-measurement 11 Balance as of June 30, 2023 $ 36

Note 12 - Income Taxes

Note 12 - Income Taxes	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. The Company recorded no provision or benefit for income tax expense for the six June 30, 2024 2023 For all periods presented, the pretax losses incurred by the Company received no not The Company has no June 30, 2024

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Glytech Agreement The Company licenses patents that are owned by Glytech, LLC (“ Glytech Glytech Agreement three June 30, 2024 2023 six June 30, 2024 2023 The Fourth Amendment to the Glytech Agreement, effective as of December 31, 2020, not NRX‑100 NRX‑101. November 6, 2022 no March 31, 2024, ( Glytech Equity twenty 20 no twenty not March 31, 2024. Consulting Agreement with Dr. Jonathan Javitt The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and is the Chairman of the Board of Directors. Therefore, the services provided to the Company are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until March 8, 2022 three June 30, 2024 2023 six June 30, 2024 2023 On March 29, 2023, March 8, 2022 March 8, 2024 one Javitt Amendment 2023, may 2024 March 2024, June 30, 2024 December 31, 2023 The Javitt Amendment also provides, subject to the approval of the Board of Directors, for a grant of 50,000 shares of restricted stock of the Company under the Company’s 2021 June 30, 2024 not The term “New Drug Application Date” means the date upon which the FDA files the Company’s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term “New Drug Approval Date” means date upon which the FDA has both approved the Company’s Antidepressant Drug Regimen and listed the Company’s Antidepressant Drug Regimen in the FDA’s “Orange Book”. The term “Antidepressant Drug Regimen” means NRX- 101, 100 Consulting Agreement with Zachary Javitt Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company’s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of less than $0.1 million during the three six June 30, 2024 2023 Included in accounts payable were less than $0.1 million due to the above related parties as of June 30, 2024 December 31, 2023

Note 14 - Subsequent Event

Note 14 - Subsequent Event	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	14. At-The Market Offering Agreement From July 11, 2024 July 30, 2024, ATM Purchase Agreements June 30, 2024, Nasdaq Listing Compliance On August 6, 2024, Letter Nasdaq June 14, 2024 August 5, 2024, MVLS $35 5550 2 MVLS Requirement 5810 3 180 February 3, 2024 Securities Purchase Agreement On August 12, 2024, SPA three $16.3 Notes 1.4 Warrants first The Notes bear interest at the rate of 6% per annum and mature in 15 months following their date of issuance. The Notes may may not may $2.4168 seven The Warrants have a term of 5 years, and exercise price of $2.42 Settlement Agreement On August 12, 2024 ( Effective Date Agreement two first five second 60 not

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. None 10b5 1 10b5 1 June 30, 2024 408 not 10b5–1 June 30, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP FASB ASC SEC not not may
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible note payable, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may
Risks and Uncertainties [Policy Text Block]	Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not third
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments FASB ASC Topic 820, Fair Value Measurements ASC 820 The accounting guidance classifies fair value measurements in one three Level 1: Level 2: 1 Level 3: no 11
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not may, June 30, 2024 not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three may
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers ASC 606 not may may The Company enters into contractual arrangements that may 606, may The License Agreement (the “ License Agreement Alvogen 6 606. 606, 606, five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five At contract inception, once the contract is determined to be within the scope of ASC 606, may not The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may not The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. The Company’s revenue arrangements may Milestone Payments: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first not Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Research Services: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note 6
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.
Deferred Charges, Policy [Policy Text Block]	Non-cancellable Contracts The Company may may
Debt, Policy [Policy Text Block]	Convertible Note Payable and Fair Value Election As permitted under FASB ASC Topic 825, ASC 825 The Company estimates the fair value of the note payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility and volume volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimate its expected future equity and volume volatility based on the historical volatility of both its Common Stock price and Common Stock trading volume utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six December 31, 2023, June 30, 2024,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations and comprehensive loss based upon the underlying individual’s role at the Company.
Derivatives, Policy [Policy Text Block]	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ASC 480 815, Derivatives and Hedging ASC 815 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not 9 11 Modification of Warrants A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may
Stockholders' Equity, Policy [Policy Text Block]	Preferred Stock In accordance with ASC 480, not 815 40, Derivatives and Hedging Contracts in an Entity s Own Equity not not 815.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ASC 740 not not 740. not not
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share The Company applies the two two no two not Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. Six months ended June 30, 2024 2023 Stock options 161,437 254,885 Restricted stock awards 66,666 100,000 Common stock warrants 4,069,240 3,002,159
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. For the six June 30, 2024 no

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six months ended June 30, 2024 2023 Stock options 161,437 254,885 Restricted stock awards 66,666 100,000 Common stock warrants 4,069,240 3,002,159

Note 4 - Prepaid Expense and _2

Note 4 - Prepaid Expense and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) Prepaid expense and other current assets: Prepaid insurance $ 1,500 $ 1,078 Prepaid clinical development costs 830 871 Other prepaid expense 646 334 Other current receivables 6 6 Total prepaid expense and other current assets $ 2,982 $ 2,289

Note 5 - Accrued and Other Cu_2

Note 5 - Accrued and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) Accrued and other current liabilities: Refund liability (see Note 6) $ 3,826 $ — Professional services 3,593 2,686 Accrued employee costs 1,062 835 Accrued research and development expense 900 1,112 Other accrued expense 213 81 Total accrued and other current liabilities $ 9,594 $ 4,714

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Milestone Payments [Table Text Block]	End of Phase I Clinical Trials of Licensed Product (completed) $ 100,000 End of Phase II Clinical Trials of Licensed Product (completed) $ 250,000 End of Phase III Clinical Trials of Licensed Product $ 250,000 First Commercial Sale of Licensed Product in U.S. $ 500,000 First Commercial Sale of Licensed Product in Europe $ 500,000 Annual Revenues Reach $100,000,000 $ 750,000

Note 9 - Equity (Tables)

Note 9 - Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Average Weighted Aggregate Total Remaining Average Intrinsic Value Warrant Shares Term Exercise Price (in thousands) Outstanding as of December 31, 2023 3,321,499 3.91 $ 23.01 $ 180 Issued 718,348 Expired (5,510 ) Outstanding as of March 31, 2024 4,034,337 3.68 19.61 807 Issued 34,903 Outstanding as of June 30, 2024 4,069,240 3.44 $ 19.47 $ —

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of shares Weighted average exercise price Weighted average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2023 264,983 $ 18.30 7.7 $ 75 Expired/Forfeited (89,546 ) Outstanding as of March 31, 2024 175,437 $ 18.60 8.4 $ 40 Expired/Forfeited (14,000 ) Outstanding as of June 30, 2024 161,437 $ 21.18 7.5 $ — Options vested and exercisable as of June 30, 2024 126,882 $ 25.18 7.0 $ —
Nonvested Restricted Stock Shares Activity [Table Text Block]	Awards Weighted Average Grant Date Fair Value Balance as of December 31, 2023 (unvested) 124,166 $ 5.20 Vested (57,500 ) 4.64 Balance as of March 31, 2024 (unvested) 66,666 5.66 Vested — — Balance as of June 30, 2024 (unvested) 66,666 $ 5.66
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 (Unaudited) Stock-based compensation expense General and administrative $ 72 $ 443 $ 283 $ 1,034 Research and development 25 101 56 205 Total stock-based compensation expense $ 97 $ 544 $ 339 $ 1,239

Note 11 - Fair Value Measurem_2

Note 11 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Description Level June 30, 2024 December 31, 2023 Assets: (Unaudited) Money Market Account 1 $ 475 $ 3,874 Liabilities: Warrant liabilities (Note 9) 3 $ 8 $ 17 Convertible note payable (Note 7) 3 $ 7,651 $ 9,161
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	June 30, 2024 2023 Stock price on valuation date $ 2.44 $ 4.84 Time to expiration 0.17 0.84 Note market interest rate 20.6 % 8.9 % Equity volatility 145.0 % 100.0 % Volume volatility 560.0 % 455.0 % Risk-free rate 5.48 % 5.42 % Probability of default 50.0 % 6.5 % June 30, 2024 2023 Stock price on valuation date $ 2.44 $ 6.60 Exercise price per share $ 115.00 $ 115.00 Expected life 1.90 3.15 Volatility 176.9 % 175.1 % Risk-free rate 4.8 % 5.3 % Dividend yield 0.0 % 0.0 % Fair value of warrants $ 0.60 $ 7.93
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value of the Note as of December 31, 2023 $ 9,161 Conversions and repayments of principal and interest (shares and cash) (2,700 ) Fair value adjustment through earnings 318 Fair value adjustment through accumulated other comprehensive loss — Fair value of the Note as of March 31, 2024 6,779 Conversions and repayments of principal and interest (shares and cash) — Fair value adjustment through earnings 23 Default penalty 849 Fair value adjustment through accumulated other comprehensive loss — Fair value of the Note as of June 30, 2024 $ 7,651 Convertible note payable - current portion $ 7,651 Convertible note payable, net of current portion $ — Fair value of the Note as of December 31, 2022 $ 10,525 Conversions and repayments of principal and interest (shares and cash) — Fair value adjustment through earnings 1,770 Fair value adjustment through accumulated other comprehensive loss (106 ) Fair value of the Note as of March 31, 2023 12,189 Conversions and repayments of principal and interest (shares and cash) (288 ) Fair value adjustment through earnings 665 Fair value adjustment through accumulated other comprehensive loss 128 Fair value of the Note as of June 30, 2023 $ 12,694 Convertible note payable - current portion $ 12,694 Convertible note payable, net of current portion $ — Balance as of December 31, 2023 $ 17 Loss upon re-measurement 9 Balance as of March 31, 2024 26 Gain upon re-measurement (18 ) Balance as of June 30, 2024 $ 8 Balance as of December 31, 2022 $ 37 Gain upon re-measurement (12 ) Balance as of March 31, 2023 25 Loss upon re-measurement 11 Balance as of June 30, 2023 $ 36

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($) $ in Thousands		6 Months Ended
	Aug. 12, 2024	Jun. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax		$ 0
Cash and Cash Equivalents, at Carrying Value		$ 1,898	$ 4,595
Streetervile Complaint [Member] | Subsequent Event [Member] | Convertible Debt [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 5,600

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Millions		1 Months Ended
	Apr. 01, 2024 $ / shares shares	Apr. 30, 2024 shares	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001		$ 0.001	$ 0.001
Stock Issued During Period, Shares, Reverse Stock Splits (in shares) | shares	0	73,040
Money Market Funds [Member]
Cash, Uninsured Amount | $			$ 1.3
Stockholders' Equity, Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	161,437	254,885
Restricted Stock [Member]
Antidilutive securities (in shares)	66,666	100,000
Warrant [Member]
Antidilutive securities (in shares)	4,069,240	3,002,159

Note 4 - Prepaid Expense and _3

Note 4 - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Prepaid insurance	$ 1,500	$ 1,078
Prepaid clinical development costs	830	871
Other prepaid expense	646	334
Other current receivables	6	6
Total prepaid expense and other current assets	$ 2,982	$ 2,289

Note 5 - Accrued and Other Cu_3

Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Refund liability (see Note 6)	$ 3,826	$ 0
Professional services	3,593	2,686
Accrued employee costs	1,062	835
Accrued research and development expense	900	1,112
Other accrued expense	213	81
Total accrued and other current liabilities	$ 9,594	$ 4,714

Note 6 - Alvogen Licensing Ag_2

Note 6 - Alvogen Licensing Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Jun. 30, 2024	Feb. 29, 2024	Feb. 07, 2024	Dec. 31, 2023	Jun. 02, 2023
Customer Refund Liability, Current	$ 3,826			$ 0
Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 4
Warrants and Rights Outstanding, Term (Year)			3 years
Warrants and Rights Outstanding			$ 1,300
Alvogen Licensing Agreement [Member]
License Agreement, Initial Payment		$ 4,000			$ 9,000
License Agreement, Accelerating Payment		$ 5,000
Customer Refund Liability, Current	3,800
Stock Subscriptions Receivable, Write Off	$ 1,300
Alvogen Licensing Agreement [Member] | Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 1,300

Note 7 - Debt (Details Textual)

Note 7 - Debt (Details Textual) - USD ($)							3 Months Ended		6 Months Ended
	Jul. 29, 2024	Apr. 24, 2024	Feb. 09, 2024	Jul. 10, 2023	Jul. 07, 2023	Nov. 04, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Loss on Contract Termination for Default							$ 849,000	$ 0	$ 849,000	$ 0
Streetervile Complaint [Member]
Loss Contingency, Damages Sought, Value		$ 6,537,027
Streetervile Complaint [Member] | Subsequent Event [Member]
Stockholders Equity Note Spinoff Transaction, Percentage	49%
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage						9%
Debt Instrument, Face Amount						$ 11,000,000
Debt Instrument, Term (Month)						18 months
Debt Instrument, Unamortized Discount						$ 1,000,000
Proceeds from Issuance of Debt						$ 10,000,000
Debt Instrument, Prepayment Percentage						110%
Debt Instrument, Redemption Amount						$ 1,000,000
Debt Instrument, Redemption Price, Percentage						10%
Debt Instrument, Redemption Conversion Price, Percentage						85%
Debt Instrument, Conditional Default Interest Rate						18%
Debt Instrument, Convertible, Maximum Percentage of Equity Issuable						9.99%
Repayments of Debt									100,000
Debt Instrument, Periodic Payment			$ 400,000
Liabilities, Fair Value Adjustment							100,000	$ 300,000	700,000	$ 2,400,000
Interest Expense, Debt							100,000
Redemption Premium									200,000
Debt Conversion, Converted Instrument, Amount							100,000		200,000
Loss on Contract Termination for Default							800,000
Long-Term Debt, Gross							$ 6,500,000		$ 6,500,000		$ 8,300,000
Convertible Debt [Member] | Convertible Note Amendment 2 [Member]
Repayments of Debt				$ 1,800,000
Debt Instrument, Periodic Payment					$ 400,000
Convertible Debt [Member] | Convertible Note Amendment 2 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment					$ 1,000,000
Convertible Debt [Member] | Convertible Note Amendment 3 [Member]
Repayments of Debt			1,100,000
Debt Instrument, Periodic Payment			$ 400,000

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)				3 Months Ended	6 Months Ended
	Aug. 12, 2024	Jul. 29, 2024	Apr. 24, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 16, 2022	Apr. 16, 2021
Streetervile Complaint [Member]
Loss Contingency, Damages Sought, Value			$ 6,537,027
Streetervile Complaint [Member] | Subsequent Event [Member]
Stockholders Equity Note Spinoff Transaction, Percentage		49%
Streetervile Complaint [Member] | Subsequent Event [Member] | Convertible Debt [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 5,600,000
Sarah Herzog Memorial Hospital License Agreement [Member]
License Agreements, Milestone Payments, Conditional Reduction Percentage					25%
License Agreement, Milestone Payment					$ 0	$ 0
Payments for Royalties				$ 0		$ 0
License Agreement, Maintenance Fee							$ 150,000	$ 100,000
Sarah Herzog Memorial Hospital License Agreement [Member] | Maximum [Member]
Royalty Percentage					8.50%
Sarah Herzog Memorial Hospital License Agreement [Member] | Products Covered By Licensed Patents [Member]
Royalty Percentage					1%
Sarah Herzog Memorial Hospital License Agreement [Member] | Products Covered by Valid Claims [Member]
Royalty Percentage					2.50%

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details) - Sarah Herzog Memorial Hospital License Agreement [Member] - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
End of Phase I Clinical Trials of Licensed Product (completed)	$ 0	$ 0
End of Phase I Clinical Trials of Licensed Product [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	100,000
End of Phase II Clinical Trials of Licensed Product [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	250,000
End of Phase III Clinical Trials of Licensed Product [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	250,000
First Commercial Sale of Licensed Product in U.S. [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	500,000
First Commercial Sale of Licensed Product in Europe [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	500,000
Annual Revenue Threshold [Member]
End of Phase I Clinical Trials of Licensed Product (completed)	$ 750,000

Note 9 - Equity (Details Textua

Note 9 - Equity (Details Textual) $ / shares in Units, $ in Thousands										1 Months Ended			2 Months Ended	3 Months Ended			6 Months Ended
	May 23, 2024 USD ($) $ / shares shares	Apr. 18, 2024 USD ($) $ / shares shares	Apr. 01, 2024 $ / shares shares	Mar. 06, 2024 USD ($)	Feb. 29, 2024 USD ($) $ / shares shares	Feb. 28, 2024 USD ($) $ / shares shares	Feb. 27, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($) shares	Aug. 14, 2023 USD ($)	Apr. 30, 2024 shares	Mar. 31, 2024 shares	Aug. 31, 2023 USD ($) shares	Apr. 15, 2024 USD ($) shares	Jun. 30, 2024 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Apr. 19, 2024 USD ($) shares	Mar. 28, 2024 shares	Mar. 11, 2024 $ / shares	Mar. 05, 2024 USD ($) shares	Feb. 07, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares	May 24, 2021 $ / shares shares
Common Stock, Shares, Issued (in shares)			9,600,000											10,791,630			10,791,630			95,700,000				8,391,940
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)			0							73,040
Preferred Stock, Shares Authorized (in shares)														50,000,000			50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares														$ 0.001			$ 0.001
Common Stock, Shares Authorized (in shares)														500,000,000			500,000,000							500,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.001											$ 0.001			$ 0.001							$ 0.001
Stock Issued During Period, Value, Conversion of Convertible Securities | $															$ 0
Proceeds from Issuance of Private Placement | $																	$ 1,027	$ 8,122
Class of Warrant or Right, Outstanding (in shares)											4,034,337			4,069,240	4,034,337		4,069,240							3,321,499
Fair Value Adjustment of Warrants | $														$ (18)		$ 11	$ (9)	(1)
Common Stock, Shares, Outstanding (in shares)			9,600,000											10,791,630			10,791,630			95,700,000				8,391,940
February Warrants [Member]
Warrants and Rights Outstanding, Term (Year)						5 years
Warrants and Rights Outstanding | $						$ 500
February Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input						3.59
February Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input						3.8
February Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						5
February Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						1.781
February Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.0426
February Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0
Substitute Warrants [Member]
Fair Value Adjustment of Warrants | $														$ 100		100	$ 100	100
Substitute Warrants [Member] | Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement																									0.316
Class of Warrant or Right, Outstanding (in shares)																									3,792,970
Public Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								344,886	345,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																									$ 115
Class of Warrant or Right, Outstanding (in shares)														3,448,856			3,448,856								3,450,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																									0.1
Private Placement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														13,625			13,625
Class of Warrant or Right, Outstanding (in shares)														136,250			136,250
Fair Value Adjustment of Warrants | $														$ 100		$ 100	$ 100	$ 100
February Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						25,000
Warrants and Rights Outstanding, Term (Year)						5 years
Warrants and Rights Outstanding | $						$ 100
February Underwriter Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input						3.05
February Underwriter Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input						3.3
February Underwriter Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						5
February Underwriter Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						1.781
February Underwriter Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.0426
February Underwriter Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0
Underwriter Overallotment Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																						3,750
Warrants and Rights Outstanding | $																			$ 100			$ 100
Underwriter Overallotment Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	3.62																		3.04			3.05
Underwriter Overallotment Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	3.63																		3.63			3.3
Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5																		5			5
Underwriter Overallotment Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.781																		1.781			1.781
Underwriter Overallotment Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0452																		0.0466			0.0412
Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0																		0			0
Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																							419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																							$ 4
Warrants and Rights Outstanding, Term (Year)																							3 years
Warrants and Rights Outstanding | $																							$ 1,300
Class of Warrant or Right, Beneficial Ownership Limitation																							4.99%
Alvogen and Lotus Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																							4.1
Alvogen and Lotus Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																							4
Alvogen and Lotus Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																							3
Alvogen and Lotus Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																							1.38
Alvogen and Lotus Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																							0.042
Alvogen and Lotus Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																							0
Maximum [Member] | Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Beneficial Ownership Limitation																							9.99%
ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)													282,452
Stock Issued During Period, Value, New Issues | $									$ 4,900				$ 1,400	$ 1,228	$ 179
ATM Offering [Member] | Minimum [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares																					$ 4.643
ATM Offering [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares																					$ 7.1
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					270,000	270,000
Stock Issued During Period, Value, New Issues | $															$ 1,027
Private Placement, Premium Percentage					26.70%
Proceeds from Issuance of Private Placement | $					$ 1,000
Private Placement [Member] | February Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					270,000	270,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 3.8	$ 3.8
February Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)							500,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares							$ 2.76
Share Price (in dollars per share) | $ / shares							$ 3
Proceeds from Issuance or Sale of Equity | $				$ 200			$ 1,300
Payments of Stock Issuance Costs | $				$ 200			$ 400
February Overallotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)							75,000
April Underwriter Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		607,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 3.3
April Overallotment Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	91,050	91,050
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 3.3
Proceeds from Issuance or Sale of Equity | $	$ 200
Payments of Stock Issuance Costs | $	$ 100
April 2024 Offering [Member]
Payments of Stock Issuance Costs | $		$ 400
Proceeds from Issuance of Common Stock | $		$ 1,600
April 2024 Offering [Member] | April Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,553																		30,350
Warrants and Rights Outstanding, Term (Year)																			6 years
April 2024 Offering [Member] | April Overallotment Warrants [Member]
Warrants and Rights Outstanding, Term (Year)																			5 years
Streeterville Capital, LLC [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)								143,648
Stock Issued During Period, Value, Conversion of Convertible Securities | $								$ 400
Preferred Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)														0
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)															0
Stock Issued During Period, Value, Conversion of Convertible Securities | $															$ 0
Preferred Stock [Member] | ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)														0	0
Stock Issued During Period, Value, New Issues | $														$ 0	$ 0
Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)															0
Stock Issued During Period, Value, New Issues | $															$ 0
Conversion of Series A Preferred Stock to Preferred Stock [Member] | Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)											300,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)														12,000,000			12,000,000
Stock Issued During Period, Shares, New Issues (in shares)												3,000,000
Stock Issued During Period, Value, New Issues | $												$ 1,200
Preferred Stock, Shares Issued (in shares)														0			0
Preferred Stock, Shares Outstanding (in shares)														0			0
Series A Preferred Stock [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)														0
Conversion of Stock, Shares Converted (in shares)															3,000,000
Series A Preferred Stock [Member] | Preferred Stock [Member] | ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)														0	0
Stock Issued During Period, Value, New Issues | $														$ 0	$ 0
Series A Preferred Stock [Member] | Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)															0
Stock Issued During Period, Value, New Issues | $															$ 0
Series A Preferred Stock [Member] | Conversion of Series A Preferred Stock to Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)											3,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			10

Note 9 - Equity - Schedule of W

Note 9 - Equity - Schedule of Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Outstanding as of December 31, 2023 (in shares)	4,034,337	3,321,499
Outstanding as of December 31, 2023 (Year)	3 years 5 months 8 days	3 years 8 months 4 days	3 years 10 months 28 days
Outstanding as of December 31, 2023 (in dollars per share)	$ 19.47	$ 19.61	$ 23.01
Outstanding as of December 31, 2023	$ 0	$ 807	$ 180
Issued (in shares)	34,903	718,348
Expired (in shares)		(5,510)
Outstanding as of March 31, 2024 (in shares)	4,069,240	4,034,337	3,321,499

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) $ / shares in Units, $ in Thousands				3 Months Ended		6 Months Ended		30 Months Ended
	Jan. 01, 2024 shares	Dec. 28, 2023 USD ($) $ / shares shares	Jul. 12, 2022 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Mar. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Jan. 01, 2022	May 24, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				161,437		161,437		161,437	175,437	264,983
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares				$ 21.18		$ 21.18		$ 21.18	$ 18.6	$ 18.3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0		0
Share-Based Payment Arrangement, Expense | $				$ 97	$ 544	$ 339	$ 1,239
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0%
Share-Based Payment Arrangement, Expense | $				100		$ 300
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $				100		$ 100		$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year 2 months 12 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		57,500
Share-Based Payment Arrangement, Expense | $				100	$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $				$ 200		$ 200		$ 200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares		$ 4.6
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $		$ 300
Restricted Stock [Member] | Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)			3 years
The 2016 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				347,200		347,200		347,200
The 2016 Omnibus Incentive Plan [Member] | Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement												0.316
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)												289,542
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares												$ 51
The 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				955,281		955,281		955,281
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	83,920	200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares											1%
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)								608,365
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				346,916		346,916		346,916

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Schedule of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Outstanding, balance (in shares)	175,437	264,983	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 18.6	$ 18.3	$ 18.3
Outstanding, weighted average remaining contractual term (Year)	7 years 6 months	8 years 4 months 24 days		7 years 8 months 12 days
Outstanding, aggregate intrinsic value	$ 0	$ 40	$ 0	$ 75
Expired/Forfeited (in shares)		(89,546)	(14,000)
Outstanding, balance (in shares)	161,437	175,437	161,437	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 21.18	$ 18.6	$ 21.18	$ 18.3
Options vested and exercisable (in shares)	126,882		126,882
Options vested and exercisable, weighted average exercise price (in dollars per share)	$ 25.18		$ 25.18
Options vested and exercisable, weighted average remaining contractual term (Year)			7 years
Options vested and exercisable, aggregate intrinsic value	$ 0		$ 0

Note 10 - Stock-based Compens_5

Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Balance (unvested) (in shares)	66,666	124,166
Unvested, weighted average grant date fair value (in dollars per share)	$ 5.66	$ 5.66	$ 5.2
Vested (in shares)	0	(57,500)
Vested, weighted average grant date fair value (in dollars per share)	$ 0	$ 4.64
Vested (in shares)	0	57,500
Balance (unvested) (in shares)	66,666	66,666

Note 10 - Stock-based Compens_6

Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-based compensation expense	$ 97	$ 544	$ 339	$ 1,239
General and Administrative Expense [Member]
Stock-based compensation expense	72	443	283	1,034
Research and Development Expense [Member]
Stock-based compensation expense	$ 25	$ 101	$ 56	$ 205

Note 11 - Fair Value Measurem_3

Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Warrant liabilities (Note 9)	$ 8	$ 17
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Money Market Account	475	3,874
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Warrant liabilities (Note 9)	8	17
Convertible note payable (Note 7)	$ 7,651	$ 9,161

Note 11 - Fair Value Measurem_4

Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)	Jun. 30, 2024 $ / shares	Dec. 31, 2023	Jun. 30, 2023 $ / shares
Warrants [Member]
Fair value of warrants (in dollars per share)	$ 0.6		$ 7.93
Measurement Input, Share Price [Member] | Convertible Debt [Member]
Measurement input	2.44	4.84
Measurement Input, Share Price [Member] | Warrants [Member]
Warrant measurement input	2.44		6.6
Measurement Input, Expected Term [Member] | Convertible Debt [Member]
Measurement input	0.17	0.84
Measurement Input, Expected Term [Member] | Warrants [Member]
Warrant measurement input	1.9		3.15
Measurement Input, Exercise Price [Member] | Warrants [Member]
Warrant measurement input	115		115
Measurement Input, Market Rate [Member[ | Convertible Debt [Member]
Measurement input	0.206	0.089
Measurement Input, Price Volatility [Member] | Convertible Debt [Member]
Measurement input	1.45	1
Measurement Input, Price Volatility [Member] | Warrants [Member]
Warrant measurement input	1.769		1.751
Measurement Input, Volume Volatility [Member] | Convertible Debt [Member]
Measurement input	5.60	4.55
Measurement Input, Risk Free Interest Rate [Member] | Convertible Debt [Member]
Measurement input	0.0548	0.0542
Measurement Input, Risk Free Interest Rate [Member] | Warrants [Member]
Warrant measurement input	0.048		0.053
Measurement Input, Expected Dividend Rate [Member] | Warrants [Member]
Warrant measurement input	0		0
Measurement Input, Probability of Default [Member] | Convertible Debt [Member]
Measurement input	0.50	0.065

Note 11 - Fair Value Measurem_5

Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Convertible note payable - current portion	$ 7,651		$ 12,694
Convertible note payable, net of current portion	0		0
Convertible Debt [Member]
Fair value of the Note as of December 31, 2023	6,779	$ 9,161	12,189	$ 10,525
Conversions and repayments of principal and interest (shares and cash)	0	(2,700)	(288)	0
Fair value adjustment through earnings	23	318	665	1,770
Fair value adjustment through accumulated other comprehensive loss	0	0	128	(106)
Default penalty	849
Fair value of the Note as of March 31, 2024	7,651	6,779	12,694	12,189
Warrants [Member]
Fair value of the Note as of December 31, 2023	26	17	25	37
Fair value adjustment through earnings	(18)	9	11	(12)
Fair value of the Note as of March 31, 2024	$ 8	$ 26	$ 36	$ 25

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Expense (Benefit)	$ 0	$ 0

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Mar. 29, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Nov. 06, 2022
Accounts Payable, Current		$ 5,015		$ 5,015		$ 4,632
Glytech License Agreement [Member]
Related Party Transaction, Amounts of Transaction		100	$ 100	100	$ 100
Glytech License Agreement [Member] | NRX Pharmaceuticals, Inc [Member] | Minimum [Member]
Investment Owned, Fair Value							$ 50,000
Consultation Agreement with Dr. Jonathan Javitt [Member]
Related Party Transaction, Amounts of Transaction		200	100	400	$ 500
Consultation Agreement with Zachary Javitt [Member]
Related Party Transaction, Amounts of Transaction		100	$ 100
Consulting Agreement, Annual Payment	$ 600
Consulting Agreement, Monthly Payment	100
Consulting Agreement, Performance Bonus, Target Value	$ 300
Accrued Bonuses, Current		300		300		200
Accounts Payable, Current		$ 100		$ 100		$ 100
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	50,000
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Application Date [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	25,000
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Approval Date [member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	25,000

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - USD ($) $ / shares in Units, $ in Millions				1 Months Ended
	Aug. 12, 2024	Aug. 01, 2024	Nov. 04, 2022	Jul. 30, 2024
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage			9%
Debt Instrument, Term (Month)			18 months
Subsequent Event [Member] | Streetervile Complaint [Member] | Convertible Debt [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 5.6
Litigation Settlement, Payment Installment One	2.5
Litigation Settlement, Payment Installment Two	$ 3.1
Subsequent Event [Member] | Senior Secured Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage		6%
Debt Instrument, Term (Month)		15 months
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.4168
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		92%
ATM Purchase Agreements [Member] | Subsequent Event [Member] | Unregistered Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)				103,063
Proceeds from Issuance of Common Stock				$ 0.3
ATM Purchase Agreements [Member] | Subsequent Event [Member] | Unregistered Common Stock [Member] | Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 2.421
ATM Purchase Agreements [Member] | Subsequent Event [Member] | Unregistered Common Stock [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 2.528
Securities Purchase Agreement [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.42
Securities Purchase Agreement [Member] | Subsequent Event [Member] | Maximum [Member]
Proceeds from Issuance or Sale of Equity		$ 16.3
Proceeds from Convertible Debt		16.3
Proceeds from Issuance of Warrants		$ 1.4